[Pharmboy46]

Part of me agrees that the FDA is already in the big pharma’s back pocket. A greater part of me thinks in ATNM’s case at least, the delay may be more due to 1. The limited resources the company has to provide a viable NDA. 2. The impact of ATNM’s treatment vs. say the COVID vaccine in terms of patients served.

[timberwolf7]

I am starting to wonder if the 'length' of time to get something approved is relational to whether its a 'baby bio' vs one of the big pharma - fda 'revolving' door companies up for approval.

And yeah, the covid scam/hoax demonstrated how things 'really' work when 'something' is 'desired' didn't it.

[Legend431]

Great things are ahead indeed

[Pharmboy46]

Wow, great information! Thanks for sharing.

[oldstocks]

Found this on stocktwits
https://stocktwits.com/resume777/message/544196854
For those wondering what’s going on behind the scenes. Iomab-B, $ATNM lead PHIII complete cancer treatment, is being presented to the Department of Health & Human Services Centers for Medicare & Medicaid Services on September 12, 2023 for the determination of Iomab-B ICD-10 codes. Used for medical claim reporting in all healthcare settings, ICD-10 codes are the primary means to establish medical necessity for payment of healthcare services and procedures.
April 2024 implementation.
It doesn’t look like they are covering these NTAPS on the zoom
https://www.cms.gov/medicare/coding/icd10/c-and-m-meeting-materials/2023-09-12-icd10-meeting-materials
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850 CENTER FOR MEDICARE ICD-10 Coordination and Maintenance Committee Meeting ICD-10-PCS Therapeutic Agent Topics Consistent with the requirements of section 1886(d)(5)(K)(iii) of the Social Security Act, applicants submitted requests to create a unique procedure code to describe the administration of a therapeutic agent, such as the option to create a new code in Section X within the International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS). CMS is soliciting public comments on the proposed coding options and any clinical questions for two procedure code topics associated with new technology add-on payment (NTAP)-related ICD-10- PCS procedure code requests that involve the administration of a therapeutic agent. The deadline to submit comments for these topics being considered for an April 1, 2024 implementation is October 13, 2023. Members of the public should send any questions or comments to the CMS mailbox at: [e-mail]. Prior to the meeting, CMS will post a question and answer document on our website at https://www.cms.gov/Medicare/Coding/ICD10/C-and-M-Meeting-Materials to address clinical or coding questions that members of the public have submitted related to the two therapeutic agents, as discussed in the following pages. At a later date, CMS will post an updated question and answer document to address any additional clinical or coding questions that members of the public may have submitted by the October 13, 2023 deadline. CMS will not be presenting the NTAP-related ICD-10-PCS procedure code requests that involve the administration of a therapeutic agent at the September 12, 2023 virtual meeting. CMS will present the NTAP-related ICD-10-PCS procedure code requests that do not involve the administration of a therapeutic agent and all non-NTAP-related procedure code requests during the virtual meeting on September 12, 2023. Comments on all procedure code proposals should be sent to the following email address: [e-mail].

Looking for info on the above I got this from ai chat
I’m sorry, but I couldn’t find any specific information about the presentation of Iomab-B’s Phase III complete cancer treatment to the Department of Health & Human Services Centers for Medicare & Medicaid Services on September 12, 2023, for the determination of Iomab-B ICD-10 codes. However, I can share that Iomab-B is a first-in-class targeted radiotherapy developed by Actinium Pharmaceuticals1. It has shown positive results in the pivotal Phase 3 SIERRA Trial for patients with active relapsed or refractory Acute Myeloid Leukemia32. The trial met its primary endpoint of durable complete remission of 6-months following initial complete remission after Hematopoietic Cell Transplantation (HCT) with a p-value of <0.000132. For more specific information regarding the presentation and ICD-10 codes, I would recommend reaching out to the relevant health authorities or Actinium Pharmaceuticals directly.

[oldstocks]

Good news premarket trade $7.68

[oldstocks]

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172761069&txt2find=atnm

[Pharmboy46]

My bet is they do but my time horizon is longer if they don’t make year’s end.

[Legend431]

So will we see BLA before the end of the year?

[Pharmboy46]

So many of these biotechs are taking “far longer than expected”. I’ve been waiting on NWBO forever (and still believe I will eventually come out with at least a 10 bagger upon approval). I hope your Cormedix bears fruit soon but I’m quickly finding out that unless you have the metaphorical “cure for COVID”, nothing happens quickly in the world of biotech!

[timberwolf7]

agree. Just that I am 'all in' on CRMD and its pending Nov 15th date with the FDA.. Looking for $12 to $15 on that one for starters. Damn delays in its approval have cost me 'opportunities' on another one as I have had to 'wait'... far longer than expected over 2 years ago.. And now a bargain on ATNM

Be nice to roll some of that one into some shares sub $8 on this one..

[Pharmboy46]

Just bought a little more to add to my small position as this is too tempting an opportunity.

[timberwolf7]

Been a while, but have been monitoring the share price trend. Also tracking the FLOAT, hope they can keep it sub 30 Mil shares (26 Mil) so that the darn 'target price' doesn't get hit like it has for one I am heavily in at the moment (delays in their approval timeline has forced ATM dilution).
And know this won't be a likeable comment, but if it can hold sub $8 into the end of the year?? With a target price of around $25-30?? Be a happy buyer for the run into their approval decision (question is, are they still on track for an NDA submission late this year??)

disclaimer: currently own none, but am bullish especially as the price has slid lower

[Legend431]

Would be nice for another update soon

[copytele]

@4 follow for you , PLEASE hit me back

[Pharmboy46]

Sorry, not sure what you’re asking. Actinium as a radioactive atom doesn’t exist naturally and is extremely rare. That being said, the company, Actinium pharmaceuticals, uses radioactive elements combined with human antibodies to fight blood cancers.

[copytele]

How valuable is raw ACTINIUM I have #11 pounds?~~~~from one of my gold mines in ALASKA.

[oldstocks]

There are signals in the stock today. The Actinium Pharmaceuticals, Inc stock holds signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $7.07 and $7.48. A break-up above any of these levels will issue buy signals. A buy signal was issued from a pivot bottom point on Thursday, July 27, 2023, and so far it has risen 0.579%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price.
This is considered to be a good technical signal.

[Legend431]

Great news

[oldstocks]

NEW YORK, July 24, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Company will participate in the 2nd Annual Targeted Radiopharmaceuticals Summit in Boston, July 25 - 27, 2023. Actinium will present "Targeted Radiotherapeutics & Innovative Combinations to Alter the Treatment Outcome for Conditioning, Hematological & Solid Tumor Malignancies" on Thursday, July 27, 2023 at 12:30pm ET.

[Pharmboy46]

After my sale last year, I’ve determined that my time horizon for this stock is a lot longer and also depends on how much the price will increase after an FDA approval.

[oldstocks]

Actinium Pharmaceuticals ATNM Stock Price Target $33.25

52 Week high $15.12

The Short interest report
Last report 6/30/2023
2,140,000 shares
8.7 Dayd to Cover

Forecast is for Shorts to Cover

Actinium Pharmaceuticals Inc Stock Price Forecast for 2023
August 2023 7.289 8.189 7.289 8.21310.99 % ?
September 2023 8.162 8.852 8.162 8.8637.8 % ?
October 2023 8.892 9.328 8.833 9.3284.68 % ?
November 2023 9.351 9.244 9.244 9.466-1.16 %?
December 2023 9.221 9.193 9.193 9.325-0.3 %?

Actinium Pharmaceuticals Inc Stock Price Forecast for 2024
January 2024 9.177 9.179 9.026 9.1880.01 % ?
February 2024 9.180 8.862 8.862 9.251-3.59 %?
March 2024 8.828 9.701 8.828 9.7048.99 % ?
April 2024 9.768 9.714 9.710 9.829-0.55 %?
May 2024 9.688 9.761 9.446 9.7660.75 % ?
June 2024 9.820 9.209 9.209 9.847-6.63 %?
July 2024 9.213 9.349 9.201 9.3491.46 % ?
August 2024 9.369 10.239 9.369 10.2908.5 % ?
September 2024 10.254 10.962 10.254 10.9626.45 % ?
October 2024 10.989 11.406 10.907 11.4063.66 % ?
November 2024 11.409 11.293 11.293 11.532-1.02 %?
December 2024 11.321 11.278 11.267 11.404-0.38 %?

Actinium Pharmaceuticals Inc Stock Price Forecast for 2025
January 2025 11.259 11.226 11.099 11.259-0.29 %?
February 2025 11.283 10.915 10.915 11.319-3.38 %?
March 2025 10.917 11.825 10.917 11.8257.68 % ?
April 2025 11.862 11.787 11.787 11.903-0.64 %?
May 2025 11.756 11.810 11.512 11.8120.46 % ?
June 2025 11.882 11.291 11.291 11.915-5.24 %?
July 2025 11.311 11.404 11.270 11.4040.82 % ?
August 2025 11.410 12.318 11.410 12.3647.37 % ?
September 2025 12.329 13.057 12.320 13.0575.58 % ?
October 2025 13.056 13.449 12.985 13.4492.92 % ?
November 2025 13.544 13.369 13.369 13.613-1.31 %?
December 2025 13.391 13.349 13.349 13.480-0.31 %?

Actinium Pharmaceuticals Inc Stock Price Forecast for 2026
January 2026 13.325 13.284 13.174 13.325-0.31 %?
February 2026 13.343 13.007 13.007 13.403-2.59 %?
March 2026 12.994 13.919 12.993 13.9196.64 % ?
April 2026 13.927 13.854 13.854 13.978-0.53 %?
May 2026 13.810 13.855 13.584 13.8550.33 % ?
June 2026 13.939 13.389 13.373 13.981-4.1 %?
July 2026 13.379 13.446 13.341 13.4460.5 % ?
August 2026 13.569 14.407 13.569 14.4355.82 % ?
September 2026 14.427 15.124 14.386 15.1244.61 % ?
October 2026 15.117 15.485 15.065 15.4852.37 % ?
November 2026 15.590 15.462 15.447 15.694-0.83 %?
December 2026 15.487 15.414 15.414 15.555-0.47 %?

Actinium Pharmaceuticals Inc Stock Price Forecast for 2027
January 2027 15.377 15.341 15.251 15.377-0.24 %?
February 2027 15.402 15.104 15.104 15.482-1.97 %?
March 2027 15.078 15.983 15.053 15.9835.66 % ?
April 2027 15.986 15.908 15.908 16.052-0.49 %?
May 2027 15.869 15.990 15.661 15.9900.76 % ?
June 2027 16.032 15.459 15.459 16.052-3.71 %?
July 2027 15.442 15.489 15.415 15.4930.3 % ?
August 2027 15.596 16.505 15.596 16.5055.51 % ?
September 2027 16.496 17.184 16.457 17.1864.01 % ?
October 2027 17.166 17.518 17.140 17.5182.01 % ?
November 2027 17.632 17.559 17.528 17.771-0.41 %?
December 2027 17.554 17.467 17.467 17.628-0.5 %?

Actinium Pharmaceuticals Inc Stock Price Forecast for 2028
January 2028 17.451 17.459 17.330 17.4620.05 % ?
February 2028 17.496 17.178 17.168 17.556-1.85 %?
March 2028 17.162 18.032 17.121 18.0414.82 % ?
April 2028 18.083 18.003 18.003 18.126-0.45 %?
May 2028 17.969 18.095 17.744 18.0950.7 % ?
June 2028 18.100 17.493 17.493 18.139-3.47 %?
July 2028 17.511 17.523 17.507 17.5650.07 % ?

[Pharmboy46]

Congratulations on your treatment success! I also share your enthusiasm with ATNM but had substantially reduced my investment about a year ago. (Needed some cash). I still feel that what I have remaining will yield a solid return. Good luck with your continuing good health and your investments.

[oldstocks]

I am in ATNM Actinium Pharmaceuticals because it is a biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients.
I really do not care if i make or lose money on this stock.
I’d rather make money on my investment.
As a cancer survivor i would love to see more cancer companies with promising treatments.
ATNM will be back over the 52 week high.
Thanks to cancer treatments i will be hear to see another 52 week high.
My treatments were not a result of Actinium but radiation ?? treatment did kill my cancer.

ATNM broke over $14.50 twice in the last year.
The time to get in and hold while the price is low and hope for a run over $14 again.
I had hope and i keep that hope for ATNM

[oldstocks]

I added to my position Friday. I am in ATNM because i believe they can help people with cancer.
This is something you don’t think of until you have cancer yourself. Cancer treatments are not cheap.
Good thing for insurance.
Fact is Cancer sometimes can be beat.
Cancer will always be out there.
People will need cancer treatments.
Well time for me to get ready to drive to Orlando hospital for an injection, and again tomorrow for a pill to swallow and again Thursday for a scan to see if my treatment has worked.
My treatment is not related with any of ATNM trials or products. I just like what i see with ATNM

[Legend431]

Not a pump and dump. Atnm has a great future

[Paullee]

law of averages

[oldstocks]

Any reason for stock moving up today?

[timberwolf7]

Street target price: Avg based on yahoos finance page is $31/sh...

Something to track although they say they have a lot of cash on hand (they should they doubled up the damn share count to 25 Million) is the 'share count' which as of the end of the 1st qtr 2023 is around 25 Million..

So from a timeline standpoint, end of this year for an NDA submission.. add 9 months to that..

If I had shares right now, I would be selling the covered calls for what I could get, at the $10 level. Just don't see a reason coming in the near future to jeopardize $10/sh..

disclaimer: still don't have any, loaded with CRMD which just got their timeline clarified, sitting at $5/sh, target price $15 on 41 Million shares outstanding. And if they get the additional sector (oncology) we know they will be asking approval for, well that puts the target price north around $25+.. Just going to take till the end of the year for an FDA decision from the looks of it.

[timberwolf7]

Been watching the share price and have to say, its gotten 'attractive' again at sub $10/sh..

See that they intend to file their NDA later this year, so given the time after that for a decision (around 9 months after the NDA is accepted),

Guess I will be looking to take another 'round' with this one..

and agree, unless the fed death agency screws around with them, the data indicates is should be approvable.

disclaimer: own none, but will be looking to accumulate.. Good luck.. at least there is a timeline now..

[Pharmboy46]

Results were definitely FDA approvable. Everyone is probably just upset because no buy out was announced. Give it time, it’ll bounce back.

[blukky]

What's wrong? I don't understand! Down 5$ in two days! Why? Results are out and not so bad?

[Lonewolf1]

PUMP & DUMP

[Jaydixson1]

Seems controlled

[timberwolf7]

ATNM PR makes me think I missed something. For in the PR, they discuss their 'financial/expansion' activity in the EU..

and say the market share there MIGHT be bigger than what they have in the US.

IF this is accurate, my target price looks like its going to be 'way' low cause I didn't 'see' this coming.

And I hadn't heard anything about the EU mentioned before in terms of a revenue stream.

Be interesting to see what the analysts do with this info, what target price they start to 'update to' now.

Disclaimer: I own none, but one of my kids held onto their shares and is enjoying the run (we were selling calls for some time, so the cost basis is sub $10/sh)

[timberwolf7]

nice run in progress. My son kept his shares so he is now up some on them.

Still have a $20/sh target price due to the higher share count. Hopefully for those holding,
when they start to talk about marketing, they get better numbers in terms of reimbursement rates.

Good luck to those holding. Note, I am still following their other programs in progress, but they have
a ways to go..

Note, son will likely take what it gives and move the gains into shares of CRMD if that still hasn't gotten
the clearance from the fda to move towards its own approval.

Again, good luck

[timberwolf7]

Just thought I would drop this info on the board for those that may not have seen it.

Got a letter related to ATNM asking me to make sure I vote for the requested uptick in the number of shares
they want to make available for what appears to be 'compensation' packages. From 5 Mil to somewhere in the 8 Million range.

Thats an additional 3 Million shares on top of the more than doubling of the share count outstanding since they did the r/split down to
11 Million.

What a frigging disappointment... But as a side note, while I have unloaded my shares for another 'opportunity' (CRMD), I do intend to follow
ATNMs additional AWE related efforts cause those could be real share price boosters IF they are successful. But will be waiting for the PH 2 results before I consider buying any shares.

Good luck.

[timberwolf7]

Damn.. in MY message that I am replying to, I made reference to a company in a PH 3 that is nearing the completion of enrollment. I said NGENF, but what it should have been was NSPR.

I did buy 'some' at $1.14 after I posted that prior one, plan to keep slowly building a position in it, but it has a ways to go before the PH 3 is completed. Thanks to a 1 year 'monitoring' period post enrollment in the trial. Not too thrilled to see the share price moving up, but why I started nibbling was I expect the PH 3 to go as well as the PH 2 did (not a 'complex' development in terms of whether it will 'work' or 'not', cause the PH 3 is essentially an extension of the PH 2)

On a follow up, AVXL did release data from their Ph 2/3 EARLY stage ALZ trial. While the data 'sounds' positive, and the market 'somewhat' liked it (nice pop in the share price), they do need to clarify what they said in terms the market can 'understand' without questioning. And they did surprise late Friday with a release saying they will hold another CC on Monday pre market. So that could get interesting.

(disclaimer: only own 500 shares of AVXL at a cost basis of $8.75/sh) (intention was once the market absorbed the end of the PH 2/3 trial news, planning to keep selling covered calls once the share price settles down. And buy calls for the decision day once the NDA was accepted for review) IF I like the odds of approval. Tho have no idea how to 'put' a value on the shares till they do with what they say.

So reason for posting this was because of the clarification on NSPR and the follow up on AVXL. And note, thought I had all of my ATNM shares taken away at $7.5, but do have 2000 in an account that I had sold $12.5s (Jan expiration) against instead of the Nov $7.5s Will make a decision on whether to hold them come Jan vs keep selling covered calls in a 'take what it gives' mode. But at present, not buying any new ones.

[Pharmboy46]

Definitely agree that some of the shine is off the apple. I paired down my position (sold about 1/3 shares) last week for about a 40 percent profit- would have loved to sell more, but that’s all that was ripe for the picking. Now I wishfully hold on for approval or partnership/buyout! Happy Thanksgiving to all and good luck!

[timberwolf7]

OK, gave up my shares to the covered calls.

And now due to the increase in outstanding shares? As mentioned, no longer as 'enamored' with ATNM as I was in terms of a re-entry price. So, rolled the proceeds into more CRMD shares (target price currently at $20 (mine), $25 by some analysts) this morn at $3.95.

Also took a flier on some AVXL shares at $11.58, and then sold the Dec 2 $12 covered calls for $3/sh. They have an 'event' on the 30th of Nov, to present some data, also rumor has it that on 1 Dec, there could be an update on their PH 3 trial which is nearing completion (a roll of the dice cause their PH 2 did not give me enough to say it 'can' help Alzheimer patients with 'confidence' enough to throw a lot of money into it. So went this route and will likely lose the shares or, if the price holds, as the time premium drops, may close them out and sell another round. Will see.

But one last comment, check out NGENF. They are in a PH 3, only 8.3 Mil shares outstanding, but an Israeli company. They are supposed to complete enrolling their last trial participant by the end of the 1st qtr 2023. Then a year follow up. I don't own any at the moment, but plan to start accumulating after they announce the last enrollment occurred. Target price conservatively, $4-5, suspect higher, but start low and see how the numbers shake out later. So a buy at less than $1.50 could be a decent return.

Good luck. and damn them for doubling up the share count and its impact on the potential return.

[Pharmboy46]

But imagine if you were one of the ones 'chasing and buying' when it ran up, especially the one(s) that paid up around the peak price.

So True. I was just venting. Just hating the process/ bad timing I guess.

[timberwolf7]

It will see the target price IF its approved and sales commence. Thats when the market will start to price in its potential. Can't expect it to happen now in this market environment, especially when its a non-exciting development with limited 'revenue' potential. (ie, its not an alzheimer or cancer drug for example)..

So between now and say the next 3 months, sell covered calls, get what you can for them to reduce your cost basis while you wait.

In the meantime, check out CRMD. Its a gift at $3, target price on it ranges from $20-25 on initial approval. IF they didn't run into quality issues at the manufacturers they chose to use to produce the compound, they would be $20 already, but it delayed their approval. And on top of it, this target price is based on less than 1/2 of its potential market. I know the company is already working on how to get approved for its potential total market, and the target price for that is north of $35-40/sh..

as a disclaimer: I am loaded up on CRMD shares, and just added some down here at $3 the other day. But they are looking at up to another 6-8 months for another go at the fed DEATH agency for consideration (death agency after how they 'approved' the use of the pfizer jab solution that has been hurting and killing folks, and yet the fdeath agency won't pull it from being used)

[timberwolf7]

Got to acknowledge, its NOT the company's fault that there is a process for getting approved that includes time to generate the NDA and then the FDA review (6-9 months).
So I wouldn't be bashing the company at all for whats happening to the share price cause until its approved, the drug is NOT worth anything.

And its the reason why I mentioned I doubted this would see much higher before it pulls back, why some profit taking (especially if you have an account that doesn't tax you for your trades/gains now (gets you when you start withdrawing from them instead). Or consider selling covered calls to get 'something' when it peaked.

Now for me, I am not surprised to see it pullback, especially in a weak market like this. But at the same time, not surprised it ran as strongly as it did in a weak market desperate for something to buy (momentum traders). So now we will see where it bottoms out at, and I won't be surprised to see it sub $10. Just the way the market works. But imagine if you were one of the ones 'chasing and buying' when it ran up, especially the one(s) that paid up around the peak price.

[Pharmboy46]

(Also a novice posting). I’m just posting on my frustration on holding an equity, believing in that equity’s science and even adding to my position over the past (let’s say) 6 years. During that time, watching a reverse split and significant dilution reduce my expectations to about $20/sh. after their “big news”. My understanding is that, in developing biotechs, the greatest increases come shortly following presentation of statistically significant results. Their SIERRA phase 3 results reveal an approvable winner. I’m venting on the lackluster response from the market. That’s not to say it still won’t happen but my expectations have, yet again, been tempered. Such is life with investing in developmental biotechs.